A Multicenter, Adaptive, Randomized, Controlled Trial Platform To Evaluate Safety and Efficacy Strategies and Treatments for Hospitalized Patients with Respiratory Infections
Principal Investigator
Study Number
STUDY02001933
Summary
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms